Evidence map›Paper›PMID 38993903›Full record

ArticleFrontiers in transplantation2023

Renal function at 12 months of kidney transplantation comparing tacrolimus and mycophenolate with tacrolimus and mTORi in donors with different KDPI ranges. A multicenter cohort study using propensity scoring.

Arlisson Macedo Rodrigues, Mariana Tavares Tanno, Mariana Moraes Contti, Hong Si Nga, Mariana Farina Valiatti, Silvana Daher Costa, Tainá Veras de Sandes-Freitas, Ronaldo de Matos Esmeraldo, Camila Marinho Assunção, Juliana Bastos Campos Tassi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Arlisson Macedo Rodrigues *Division of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Mariana Tavares TannoDivision of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Mariana Moraes ConttiDivision of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Hong Si NgaDivision of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Mariana Farina ValiattiDivision of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.
Silvana Daher CostaTransplant Unit, Hospital Geral de Fortaleza, Fortaleza, Brazil.
Tainá Veras de Sandes-FreitasTransplant Unit, Hospital Geral de Fortaleza, Fortaleza, Brazil.
Ronaldo de Matos EsmeraldoTransplant Unit, Hospital Geral de Fortaleza, Fortaleza, Brazil.
Camila Marinho AssunçãoTransplant Unit, Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brazil.
Juliana Bastos Campos TassiTransplant Unit, Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brazil.
Gustavo Fernandes FerreiraTransplant Unit, Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brazil.
Claudia Rosso FelipeDivision of Nephrology, Universidade Federal de São Paulo, Hospital do Rim, São Paulo, Brazil.
Jose Osmar Medina PestanaDivision of Nephrology, Universidade Federal de São Paulo, Hospital do Rim, São Paulo, Brazil.
Helio Tedesco SilvaDivision of Nephrology, Universidade Federal de São Paulo, Hospital do Rim, São Paulo, Brazil.
Luis Gustavo Modelli de Andrade *Division of Nephrology, Department of Internal Medicine, Universidade Estadual Paulista (UNESP), Botucatu, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The combination of tacrolimus/mTORi compared to tacrolimus/mycophenolate (MMF) was shown to be safe in the TRANSFORM trial. For donors with a high KDPI (Kidney Donor Profile Index), however, there are no data to support the effectiveness of this regimen. The main objective of this study was to explore the influence of the KDPI on 12-month renal function (eGFR) in patients receiving mTORi or MMF. Methods: Multicenter cohort study of four Brazilian services that use the tacrolimus with mTORi as a protocol. Data from 2008 to 2018 of the tacrolimus/mycophenolate (MMF) and tacrolimus/mTORi (mTORi) regimens in renal transplant recipients over 18 years old were collected. For better homogeneity, the propensity score was used. Afterward, the method used for group selection ("match") was the K-nearest neighbor (KNN) method. New analyses were performed on this new balanced sample, and two different subsamples were constituted based on the median KDPI. Results: The global analysis ( Discussion: The regimen using mTOR inhibitor is an effective and safe regimen when compared to the standard regimen. In addition, the scheme seems to offer additional protection against infections and may be an important ally in cases of high risk for these pathologies.

Indexed as

immunosuppressionKDPIkidney transplantationmTORimycophenolate

Identifiers

PMID38993903
PMCPMC11235318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.